Pfizer Halts Development of Oral Obesity Drug Danuglipron After Safety Review

Weight-Loss Pill Stopped After Trial Setback

Translate to Spanish or other 102 languages!

Pfizer Inc. announced today that it will discontinue the development of danuglipron (PF-06882961), an oral GLP-1 receptor agonist under investigation for chronic weight management. The decision follows a comprehensive review of clinical trial data, including a case of potential drug-induced liver injury. Image; Pfizer image source: János Korom Dr. >17 Million views from Wien, Austria, CC BY-SA 2.0 https://creativecommons.org/licenses/by-sa/2.0, via Wikimedia Commons. medication for illustration purposes
- Advertisement -

Mega Doctor News

NEW YORK — Pfizer Inc. announced today that it will discontinue the development of danuglipron (PF-06882961), an oral GLP-1 receptor agonist under investigation for chronic weight management. The decision follows a comprehensive review of clinical trial data, including a case of potential drug-induced liver injury.

The company’s dose-optimization studies (NCT06567327 and NCT06568731) had achieved key pharmacokinetic goals and identified a once-daily formulation with the potential for competitive efficacy and tolerability in Phase 3 trials. However, among more than 1,400 participants, one individual experienced asymptomatic liver enzyme elevations consistent with potential liver injury, which resolved after discontinuation of the drug.

- Advertisement -
Dr. Chris Boshoff. Image: LinkedIN

While the overall safety profile was in line with other approved drugs in the GLP-1 class, Pfizer opted to stop development after evaluating the totality of data and receiving input from regulatory authorities.

“Cardiovascular and metabolic diseases, including obesity, remain important areas of unmet medical need,” said Dr. Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer. “We plan to continue advancing a pipeline of investigational treatments, including our oral GIPR antagonist candidate and other earlier-stage obesity programs.”

Pfizer intends to present findings from the Danuglipron clinical program at a scientific forum or submit them for publication in a peer-reviewed journal. The move reflects Pfizer’s continued commitment to innovation in the obesity and metabolic health space despite challenges in drug development. Source: Pfizer.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Behavioral to Host Webinar on Coping with Holiday Stress, Dec 3

The holiday season is often described as the most wonderful time of the year. However, for many people, it can also bring feelings of stress, sadness, anxiety and loneliness.

New Book Gives Families Language to Discuss Epilepsy

Each November, National Epilepsy Awareness Month invites people to learn how to recognize and respond to a seizure. 

Study Links Higher Vitamin D Levels to Better Sleep

Higher vitamin D levels were associated with longer and less interrupted sleep in middle-aged and older adults, in a study led by researchers at the Johns Hopkins Bloomberg School of Public Health in collaboration with scientists at the National Institute on Aging.

Caring for Others Starts With Caring for Yourself

November is National Family Caregivers Month. Whether you're caring for an aging parent or a loved one with a chronic illness, caregiving can be stressful. It's important to remember taking care of yourself is just as important.
- Advertisement -